sponsored
PatientsVille.com Logo

PatientsVille

Amgen Medical Research Studies

Up-to-date List of Amgen Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Amgen Medical Research Studies

Rank Status Study
1 Recruiting Amgen 386 for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: Amgen 386;   Drug: Bevacizumab
Outcome Measures: Radiological response rates;   Radiographic response and Median progression free survival and overall survival.
2 Recruiting Effect of Amgen Investigational Product on Cellular Biomarkers in the Human Breast
Condition: Healthy Volunteer, Female, Breast
Interventions: Other: No treatment;   Drug: Denosumab - low dose;   Drug: Denosumab - high dose
Outcome Measure: Ratio of post-baseline to baseline Ki-67 index
3 Recruiting Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation
Condition: Non Hodgkin Lymphoma
Interventions: Drug: Pegfilgrastim;   Drug: Filgrastim
Outcome Measures: 3 months kinetics of lymphocyte reconstitution, in the two arms;   6 months kinetics of lymphocyte reconstitution, in the two arms;   6 months kinetics of lymphocyte subsets reconstitution by phenotyping, in the 2 arms;   Average duration of neutropenia and thrombopenia, in the 2 arms;   Number of days with temperature ≥38°, in the 2 arms;   Number of bacterial and/or viral and/or fungal infection longer than 7 days, average duration of anti-viral, anti-fungal and antibiotic treatments, in the 2 arms;   Number of red blood cell units and platelets concentrates transfused to patient, in the 2 arms;   Evaluation of duration of Filgrastim treatment, in arm "Filgrastim";   Overall survival;   Progression free survival;   Average duration of febrile neutropenia (with neutrophils<0.5 G/L and temperature ≥38°), in the 2 arms
4 Recruiting AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
Outcome Measures: Clinically significant or ≥ Grade 3 CTCAE changes in safety laboratory tests, physical examinations, ECGs, or vital signs;   PK parameters including but not limited to, maximum observed concentration (Cmax), area under the concentration-time curve (AUC) and half life (t1/2);   Objective response rate for subjects treated at MTD based on RECIST 1.1;   Development of human anti-human antibody against AMG 172;   Objective response rate for subjects not treated at MTD based on RECIST 1.1;   Clinical benefit as measured by duration of response per RECIST 1.1
5 Recruiting Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Conditions: Cancer;   Hematologic Malignancies;   Leukemia;   Myeloid Leukemia
Interventions: Drug: Arm 1- Dose Escalation;   Drug: Arm 2- Dose Expansion
Outcome Measures: Subject incidence of adverse events;   Subject incidence of dose limiting toxicities (DLTs);   Maximum observed concentration of AMG 900;   Time to maximum observed concentration of AMG 900;   Area under the plasma concentration-time curve (AUC) of AMG 900;   Half life of AMG 900;   Objective response as per Cheson Response Criteria;   Change in the number of p-Histone H3 positive cells from baseline
6 Recruiting A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Conditions: Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Solid Tumors;   Tumors
Interventions: Drug: Arm 1- Dose Escalation;   Drug: Arm 1- Dose Expansion
Outcome Measures: Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests;   PK profile: AMG 900 PK parameters including, but not limited to, maximum observed concentration (Cmax), minimum observed concentration, area under the plasma concentration-time curve and, if feasible, half-life;   Change in levels of p-Histone H3 from baseline (part 1 - dose escalation only);   Response rate in each taxane-resistant tumor type assessed per RECIST guidelines (part 2 - dose expansion only);   Change in tumor volume from baseline measured by volumetric CT or MRI;   Tumor response measured by CT or MRI and assessed per RECIST guidelines;   Change from baseline in maximum standardized uptake value (SUVmax) using 18FLT-PET/CT (part 2 - dose expansion only)
7 Recruiting Effects of Denosumab on the Pharmacokinetics of Etanercept
Conditions: Postmenopausal;   Osteopenia;   Rheumatoid Arthritis;   Osteoporosis
Interventions: Drug: Etanercept;   Drug: Denosumab
Outcome Measures: Area under the serum concentration-time curve (AUC) from 0 to 168 hours for etanercept.;   Maximum observed serum concentration (Cmax) for etanercept.;   Time to maximum serum concentration (tmax) for etanercept.;   Serum denosumab concentration.;   Serum C-telopeptide (sCTx) concentrations.
8 Recruiting Panitumumab Pediatric Study
Condition: Solid Tumors
Intervention: Drug: Panitumumab Treatment
Outcome Measures: To evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric subjects with solid tumors;   To evaluate the incidence of human anti-panitumumab antibody (HAPA) formation and to preliminarily determine if there is evidence of anti-tumor activity of panitumumab in this patient population
9 Recruiting Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients
Condition: Coronary Artery Disease
Interventions: Biological: pegfilgrastim;   Other: Placebo
Outcome Measures: Collateral flow index (CFI);   Myocardial blood flow (MBF) during hyperemia
10 Recruiting Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: ABP 501
Outcome Measures: Subject incidence of adverse events and serious adverse events;   Clinically significant changes in laboratory values and vital signs;   Incidence of anti-drug antibodies;   ACR 20 (20% improvement in American College of Rheumatology (ACR) core set measurements at all measured time points);   Disease Activity Score (DAS) 28-CRP at all timepoints
11 Unknown  Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
Condition: Solid Malignancies
Intervention: Drug: Pegfilgrastim (Neulasta, Amgen)
Outcome Measures: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 3 blood volume processed);   Side effects Number of apheresis required to achieved a graft of at least 5x10e6 CD34 cells
12 Recruiting A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Conditions: Cancer;   Cataract;   Low Bone Mineral Density;   Osteopenia;   Osteoporosis;   Prostate Cancer
Interventions: Biological: Denosumab;   Biological: Placebo
Outcome Measure: Subject incidence of lens opacification event development or progression by month 12, based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score.
13 Recruiting Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer Metastatic
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: ABP 215;   Drug: bevacizumab
Outcome Measures: Objective response rate;   Duration of response;   Progression-free survival;   Treatment-emergent adverse events;   Treatment-emergent serious adverse events;   Incidence of anti-drug antibodies;   Overall survival
14 Recruiting A Study of AMG 820 in Subjects With Advanced Solid Tumors
Conditions: Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Oncology;   Oncology Patients;   Tumors
Intervention: Drug: AMG 820
Outcome Measures: Area Under Curve (AUC) Time Frame: predose, 0.5, 1, 2, 4, 8, 24 hours post-dose;   Dose of AMG 820 where clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled is greater than 33%.;   Change in tumor associated macrophages (TAMS) as assessed by tumor biopsy at 9 weeks.
15 Recruiting Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Condition: Psoriasis
Intervention: Drug: etanercept
Outcome Measures: Efficacy of etanercept;   Safety of etanercept;   Evaluate and compare efficacy and safety in subjects with and without antibodies to adalimumab;   Effect of treatment with etanercept on patient reported outcomes
16 Recruiting To Assess the Long-term Safety of Velcalcetide in the Treatment of SHPT in Subjects With CKD on Hemodialysis
Condition: Hyperparathyroidism, Secondary
Intervention: Drug: Velcalcetide
Outcome Measures: Measure the subject incidence of adverse events reported;   Measure the occurrence of iPTH value;   Measure the occurrence of P ≤ 4.6 mg/dL;   Assess the nature, frequency, severity, and relationship to treatment of all adverse events reported;   Occurrence of cCa concentration < 7.5 mg/dL;   Assess vital signs, antibody formation to velcalcetide, and changes in the laboratory parameters of albumin, total bilirubin (TBL), AST or ALT, and alkaline phosphatase
17 Recruiting AMG 595 First-in-Human in Recurrent Gliomas
Conditions: Advanced Malignant Glioma;   Anaplastic Astrocytomas;   Glioblastoma Multiforme
Intervention: Drug: AMG 595
Outcome Measures: Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs;   PK Parameters: Cmax, Cmin, and if feasible half life - 8 time points up to 6 weeks;   Objective response in GBM tumors as assessed by Macdonald criteria;   Dose limiting toxicity used to estimate the MTD;   Clinical benefit rate;   Progressive free survival;   Overall survival;   Anti-AMG 595 antibody formation
18 Recruiting Osteonecrosis of the Jaw (ONJ) Case Registry
Condition: Osteonecrosis of the Jaw (ONJ)
Intervention:
Outcome Measures: Resolution rate and time to ONJ resolution;   Explore the relationship between rate and time to ONJ resolution with ONJ severity and staging at Registry enrollment;   Explore the relationship between rate and time to ONJ resolution with potential risk factors;   Explore the relationship between rate and time to ONJ resolution and subsequent treatment patterns for ONJ;   Explore the relationship between rate and time to ONJ resolution and treatment patterns of antiresorptive therapy
19 Recruiting A Study of AMG 337 in Subjects With Advanced Solid Tumors
Conditions: Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Oncology;   Oncology Patients;   Tumors
Intervention: Drug: AMG 337
Outcome Measures: To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.;   Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).;   Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.;   Evaluate for clinical responses associated with AMG 337 treatment according to Response Evaluation Criteria In Solid Tumors 1.1 criteria
20 Recruiting Video Impact on Neulasta Education
Condition: Breast Cancer
Interventions: Other: Educational DVD 1;   Other: Educational DVD 2
Outcome Measures: Maximum subject-reported bone pain in cycle 1;   Maximum subject-reported bone pain by cycle (2 through 4) and across cycles (up to and including 4 cycles);   Subject-reported bone pain by cycle and across cycles (up to and including 4 cycles);   AUC for subject-reported bone pain by cycle and across all cycles (up to and including 4 cycles);   Bone pain (all grade) by cycle and across cycles (up to and including 4 cycles) captured as part of AE reporting;   Severe (grade 3/4) bone pain by cycle and across cycles (up to and including 4 cycles) captured as part of AE reporting;   Use of analgesics for the treatment of bone pain by cycle and across cycles (up to and including 4 cycles)

These studies may lead to new treatments and are adding insight into Amgen etiology and treatment.

A major focus of Amgen research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Amgen